boceprevir   Click here for help

GtoPdb Ligand ID: 7876

Synonyms: EBP-520 | EBP520 | SCH-503034 | SCH503034 | Victrelis®
Approved drug
boceprevir is an approved drug (EMA & FDA (2011))
Compound class: Synthetic organic
Comment: Boceprevir is an active site-binding inhibitor of the main protease (nonstructural protein 3, NS3) of hepatitis C virus (HCV). A patent claims boceprevir for repurposing as a cathepsin A modulator [4]. More recently it has been reported to inhibit the 3CL protease (Mpro) of several coronaviruses, including SARS-CoV-2 Mpro [1-2]. An alternative enantiomer is reported in the SARS-CoV-2 Mpro/boceprevir crystal structure 6WNP, which maps to PubChem CID 71316139.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 4
Rotatable bonds 14
Topological polar surface area 150.7
Molecular weight 519.34
XLogP 2.83
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(NC(C)(C)C)NC(C(C)(C)C)C(=O)N1CC2C(C1C(=O)NC(C(=O)C(=O)N)CC1CCC1)C2(C)C
Isomeric SMILES O=C(NC(C)(C)C)N[C@@H](C(C)(C)C)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(C(=O)C(=O)N)CC1CCC1)C2(C)C
InChI InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
InChI Key LHHCSNFAOIFYRV-DOVBMPENSA-N
Bioactivity Comments
Boceprevir inhibits a number of coronavirus proteases in vitro [1]. IC50 values for Mpro (3CL proteases) are; SARS-CoV 2.5 μM, MERS-CoV 3.8 μM.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Cathepsin A Hs Inhibitor Inhibition 6.0 pIC50 - 4
pIC50 6.0 (IC50 1x10-6 M) [4]
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CoV 3C-like (main) protease SARS-CoV-2 Inhibitor Inhibition 5.9 pKi - 3
pKi 5.9 (Ki 1.18x10-6 M) [3]
Description: Inhibition of recombinat enzyme in vitro.
CoV 3C-like (main) protease SARS-CoV Inhibitor Inhibition 5.6 – 6.0 pIC50 - 1-2
pIC50 5.6 – 6.0 (IC50 2.5x10-6 – 9.49x10-7 M) [1-2]
CoV 3C-like (main) protease SARS-CoV-2 Inhibitor Inhibition 5.4 pIC50 - 3
pIC50 5.4 (IC50 4.13x10-6 M) [3]